Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox

Details Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox

1999-05-28

2000-05-30

Stockton, Laura L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514314, 546167, 5483114, 5483121, 548181, 548201, 548204, A61K 314178, A61K 31427, C07D40312, C07D40512, C07D41712

Patent

active

06069162&

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

1. Field of the Invention
This invention relates to new amide compounds and pharmaceutically acceptable salts thereof which are useful as medicament.
2. Description of the Background
Some peptide compounds have been known as described, for example, in EP 0 394 989 A2.


SUMMARY OF THE INVENTION

This invention relates to new amide compounds.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

One object of this invention is to provide the new and useful amide compounds and pharmaceutically acceptable salts thereof which possess a strong inhibitory activity on the production of nitric oxide (NO).
Another object of this invention is to provide a process for the preparation of the amide compounds and salts thereof.
A further object of this invention is to provide a pharmaceutical composition comprising said amide compound or a pharmaceutically acceptable salt thereof.
Still further object of this invention is to provide a use of said amide compounds or pharmaceutically acceptable salts thereof as a medicament for prophylactic and therapeutic treatment of NO-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock (e.g., septic shock, etc.), diabetes (e.g., insulin-dependent diabetes mellitus, etc.), diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease (e.g., ulcerative colitis, chronic colitis, etc.), cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, postherpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, and the like in human being and animals.
The object amide compounds of the present invention are novel and can be represented by the following general formula (I) ##STR3## wherein R.sup.1 is indolyl or benzofuranyl; ##STR4## in which R.sup.5 is hydrogen, lower alkoxy or halogen; R.sup.3 is hydrogen, quinolyl or phenyl which may have a suitable substituent selected from the group consisting of lower alkyl, lower alkoxy, lower alkylthio and halogen; ##STR5## in which R.sup.7 is lower alkyl or lower alkoxy.
Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include, for example, a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, citrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); and a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, gultamic acid, etc.).
In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
Suitable "lower alkyl" and "lower alkyl moiety" in the terms "lower alkylthio" and "lower alkylthio(lower)alkyl" include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, and in which more preferred one is C.sub.1 -C.sub.4 alkyl.
Suitable "lower alkoxy" includes, for example, methoxy, ethoxy, propox

REFERENCES:
patent: 5102901 (1992-04-01), Van Wijngaarden et al.

Affiliated with

Also associated with

Rating

Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl and benzofuranyl carboxamides as inhibitors of nitric ox will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1910715